Although several candidate pathways are activated in patient biopsies (Hanson et al., 2015), to our knowledge the only therapeutic intervention tested in human cells is targeting ROS with NAC (Dowling et al., 2012), which has led to a clinical trial in RYR1-related myopathy (NCT02362425). This evidence concerns the gene RYR1 and myopathy.